Eris Lifesciences Limited

NSEI:ERIS Aktierapport

Börsvärde: ₹217.0b

Eris Lifesciences Förvaltning

Förvaltning kriterier kontrolleras 4/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Amit Bakshi

Verkställande direktör

₹48.8m

Total ersättning

VD-lön i procent35.88%
Anställning som VD18.8yrs
Ägande av VD42.8%
Ledningens genomsnittliga anställningstid6.4yrs
Styrelsens genomsnittliga mandatperiod5yrs

Senaste uppdateringar av ledningen

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Recent updates

Is Eris Lifesciences Limited (NSE:ERIS) Worth ₹1.8k Based On Its Intrinsic Value?

Aug 28
Is Eris Lifesciences Limited (NSE:ERIS) Worth ₹1.8k Based On Its Intrinsic Value?

Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Jul 26
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 26%

Jun 17
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 26%

Eris Lifesciences' (NSE:ERIS) Conservative Accounting Might Explain Soft Earnings

May 26
Eris Lifesciences' (NSE:ERIS) Conservative Accounting Might Explain Soft Earnings

Earnings Miss: Eris Lifesciences Limited Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

May 23
Earnings Miss: Eris Lifesciences Limited Missed EPS By 5.9% And Analysts Are Revising Their Forecasts

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

Apr 28
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
User avatar

Semaglutide Launch Will Secure Early Position In India's GLP-1 Market

Strategic GLP-1 market entry and Bhopal facility ramp-up are expected to boost revenue and margins through innovation and operational efficiency.

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Reasonably Well

Mar 03
These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Reasonably Well

Analysts Are Updating Their Eris Lifesciences Limited (NSE:ERIS) Estimates After Its Third-Quarter Results

Feb 09
Analysts Are Updating Their Eris Lifesciences Limited (NSE:ERIS) Estimates After Its Third-Quarter Results

What You Can Learn From Eris Lifesciences Limited's (NSE:ERIS) P/E

Jan 07
What You Can Learn From Eris Lifesciences Limited's (NSE:ERIS) P/E

Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Nov 21
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

Oct 30
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Oct 15
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Sep 03
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Aug 05
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Aug 04
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Jul 13
Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 24
Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

May 10
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Mar 14
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Feb 15
Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Dec 28
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Dec 07
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Nov 11
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Jul 20
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

Nov 20
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Jun 20
These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Feb 24
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Dec 28
Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Analys av ersättningar till VD

Hur har Amit Bakshi:s ersättning förändrats jämfört med Eris Lifesciences:s resultat?
DatumTotal ersättningLönFöretagets resultat
Jun 30 2025n/an/a

₹4b

Mar 31 2025₹49m₹17m

₹4b

Dec 31 2024n/an/a

₹3b

Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹4b

Mar 31 2024₹49m₹17m

₹4b

Dec 31 2023n/an/a

₹4b

Sep 30 2023n/an/a

₹4b

Jun 30 2023n/an/a

₹4b

Mar 31 2023₹49m₹17m

₹4b

Dec 31 2022n/an/a

₹4b

Sep 30 2022n/an/a

₹4b

Jun 30 2022n/an/a

₹4b

Mar 31 2022₹46m₹26m

₹4b

Dec 31 2021n/an/a

₹4b

Sep 30 2021n/an/a

₹4b

Jun 30 2021n/an/a

₹4b

Mar 31 2021₹27m₹27m

₹4b

Dec 31 2020n/an/a

₹3b

Sep 30 2020n/an/a

₹3b

Jun 30 2020n/an/a

₹3b

Mar 31 2020₹49m₹18m

₹3b

Dec 31 2019n/an/a

₹3b

Sep 30 2019n/an/a

₹3b

Jun 30 2019n/an/a

₹3b

Mar 31 2019₹49m₹18m

₹3b

Ersättning vs marknad: Amit s total kompensation ($USD 549.52K ) är ungefär genomsnittet för företag av liknande storlek på Indian marknaden ($USD 651.51K ).

Ersättning vs inkomst: Ersättningen från Amit har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Amit Bakshi (50 yo)

18.8yrs
Anställning
₹48,776,648
Kompensation

Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Amit Bakshi
Chairman & MDno data₹48.78m42.83%
₹ 92.9b
Sachin Shah
Chief Financial Officer9.1yrs₹38.66minga uppgifter
Krishnakumar Vaidyanathan
Executive Director & COO4.4yrs₹45.78minga uppgifter
Milind Talegaonkar
Compliance Officer & Company Secretary9.1yrs₹10.66minga uppgifter
Gagan Atreja
President of Sales & Marketing3.3yrs₹12.75minga uppgifter
Inderjeet Negi
Executive Directorno data₹12.40m4.36%
₹ 9.5b
Kaushal Shah
Whole Time Directorno data₹16.82m3.28%
₹ 7.1b
Vijay Joshi
President of Medicalno data₹15.71minga uppgifter
Deepak Kapoor
Senior Vice President5.7yrs₹25.79minga uppgifter
Murari Ranganathan
President of Cardiometabolic Businessless than a year₹1.50minga uppgifter
Manish Kapoor
Vice President7.2yrs₹12.36minga uppgifter
Santosh Danavale
Vice President of Special Projects18.5yrs₹13.12minga uppgifter
6.4yrs
Genomsnittlig anställningstid
50yo
Genomsnittlig ålder

Erfaren ledning: ERIS s ledningsgrupp är erfaren och erfaren ( 6.4 års genomsnittlig anställning).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Amit Bakshi
Chairman & MD18.8yrs₹48.78m42.83%
₹ 92.9b
Krishnakumar Vaidyanathan
Executive Director & COO4.8yrs₹45.78minga uppgifter
Inderjeet Negi
Executive Director18.8yrs₹12.40m4.36%
₹ 9.5b
Kaushal Shah
Whole Time Director5.2yrs₹16.82m3.28%
₹ 7.1b
Prashant Gupta
Independent Non-Executive Director7.5yrs₹375.00kinga uppgifter
Sujesh Vasudevan
Independent Non-Executive Director3.3yrs₹4.05minga uppgifter
Kalpana Unadkat
Independent Non-Executive Director4.8yrs₹4.28minga uppgifter
Rajeev Dalal
Independent Non-Executive Director4.8yrs₹4.50minga uppgifter
5.0yrs
Genomsnittlig anställningstid
50yo
Genomsnittlig ålder

Erfaren styrelse: ERIS s styrelse anses vara erfaren ( 5 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2025/10/04 19:56
Aktiekurs vid dagens slut2025/10/03 00:00
Intäkter2025/06/30
Årlig intjäning2025/03/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Eris Lifesciences Limited bevakas av 20 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Ashwin MehtaAmbit Capital
Prashant NairAmbit Capital
Harith AhamedAvendus Spark